Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
remaining steps are practical execution items and can begin commercial efforts ahead of first shipments while leveraging its existing SKYTROFA rare endocrine commercial infrastructure. Ascendis sees a meaningful U.S. opportunity—about 2,600 patients with less than one-third currently treated —and expects uptake from both switches (FDA labeling allows next-day transition from daily therapy) and previously untreated patients drawn by data showing benefits beyond linear growth, such as improved leg alignment and reduced surgical need. Pricing is expected soon ; the company historically targets premium pricing tied to perceived superior benefits but says it will pursue a "fair" approach and rely on patient-support programs and medical-exception pathways rather than heavy payer contracting to enable access. Interested in Ascendis Pharma A/S? Here are five stocks we like better. Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S (NASDAQ:ASND) discus
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.MarketBeat
- Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]Seeking Alpha
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/2/26 - Form 144
- ASND's page on the SEC website